| Date Filed | Type | Description |
| 10/17/2022 |
4
| Societe des Produits Nestle S.A. (10% Owner) has filed a Form 4 on Axcella Health Inc.|
Txns:
| Bought 3,658,536 shares
@ $1.64, valued at
$6M
|
|
| 03/16/2022 |
4
| Societe des Produits Nestle S.A. (10% Owner) has filed a Form 4 on Axcella Health Inc.|
Txns:
| Bought 3,141,361 shares
@ $1.91, valued at
$6M
|
|
| 03/12/2021 |
3
| NESTLE SA (10% Owner) has filed a Form 3 on Prometheus Biosciences, Inc. |
| 09/09/2020 |
4
| Societe des Produits Nestle S.A. (10% Owner) has filed a Form 4 on Axcella Health Inc.|
Txns:
| Acquired 4,305,541 shares
@ $4.42, valued at
$19M
|
|
| 05/21/2020 |
4
| Nestle Health Science US Holdings, Inc. (10% Owner) has filed a Form 4 on Axcella Health Inc.|
Txns:
| Bought 1,936,842 shares
@ $4.75, valued at
$9.2M
|
|
| 04/24/2020 |
4
| Societe des Produits Nestle S.A. (10% Owner) has filed a Form 4 on Aimmune Therapeutics, Inc.|
Txns:
| Bought 1,000,000 shares
@ $31.97, valued at
$32M
Bought 525,634 preferred shares
@ $319.675, valued at
$168M
Acquired 12,727,113 shares
@ $16.11, valued at
$205M
Acquired 525,634 preferred shares
@ $161.1, valued at
$84.7M
|
|
| 04/24/2020 |
3
| Nestle Health Science US Holdings, Inc. (10% Owner) has filed a Form 3 on Aimmune Therapeutics, Inc. |
| 04/24/2020 |
4
| Nestle Health Science US Holdings, Inc. (10% Owner) has filed a Form 4 on Aimmune Therapeutics, Inc.|
Txns:
| Bought 937,500 shares
@ $32, valued at
$30M
Bought 3,237,529 shares
@ $30.27, valued at
$98M
|
|
| 02/14/2020 |
3
| Nestle Health Science US Holdings, Inc. (10% Owner) has filed a Form 3 on Axcella Health Inc. |
| 11/23/2016 |
3
| Nestle Health Science US Holdings, Inc. (10% Owner) has filed a Form 3 on Aimmune Therapeutics, Inc. |
| 07/01/2015 |
4
| Nestle Health Science US Holdings, Inc. (10% Owner) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Granted 1,333,333 shares
@ $18, valued at
$24M
|
|
| 06/29/2015 |
4
| Nestle Health Science US Holdings, Inc. (10% Owner) has filed a Form 4 on Seres Therapeutics, Inc.|
Txns:
| Converted 3,611,111 shares
@ $0
Converted 3,611,111 convertible preferred
@ $0 |
|
| 07/07/2009 |
F-6EF
| Form F-6EF -- Registration of American Depostory Receipt shares, immediately effective |
| 07/03/2008 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 12/29/2005 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 11/30/2005 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 11/22/2005 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 11/04/2005 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 09/07/2005 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 07/07/2005 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/12/2003 |
SC 13G
| NESTLE SA reports a 74.5% stake in Alcon, Inc. |
| 02/27/1998 |
SC 13G/A
| NESTLE SA reports a 13.7% stake in TRANSCEND THERAPEUTICS, INC. |
| 02/17/1998 |
5
| Form 5 -- Annual statement of changes in beneficial ownership of securities |
| 02/05/1998 |
SC 13G
| NESTLE SA reports a 13.7% stake in TRANSCEND THERAPEUTICS, INC. |